BRIEF-Merck KGaA's Bavencio drug wins EU approval for Merkel cell carcinoma

* European commission approves Bavencio (avelumab) for metastatic Merkel cell carcinoma For the full story: Further company coverage:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.